These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Alterations of p63 and p73 in human cancers. Inoue K; Fry EA Subcell Biochem; 2014; 85():17-40. PubMed ID: 25201187 [TBL] [Abstract][Full Text] [Related]
27. Contribution of p53, p63, and p73 to the developmental diseases and cancer. Tomkova K; Tomka M; Zajac V Neoplasma; 2008; 55(3):177-81. PubMed ID: 18348649 [TBL] [Abstract][Full Text] [Related]
28. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management. Hassan HM; Dave BJ; Singh RK Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526 [TBL] [Abstract][Full Text] [Related]
29. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Orzol P; Holcakova J; Nekulova M; Nenutil R; Vojtesek B; Coates PJ Histol Histopathol; 2015 May; 30(5):503-21. PubMed ID: 25510918 [TBL] [Abstract][Full Text] [Related]
30. Computational Modeling of TP63-TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics. Ozdemir ES; Gomes MM; Fischer JM Mol Cancer Ther; 2022 Dec; 21(12):1846-1856. PubMed ID: 36190964 [TBL] [Abstract][Full Text] [Related]
31. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898 [TBL] [Abstract][Full Text] [Related]
32. Family members p53 and p73 act together in chromatin modification and direct repression of alpha-fetoprotein transcription. Cui R; Nguyen TT; Taube JH; Stratton SA; Feuerman MH; Barton MC J Biol Chem; 2005 Nov; 280(47):39152-60. PubMed ID: 16203738 [TBL] [Abstract][Full Text] [Related]
33. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition. Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003 [TBL] [Abstract][Full Text] [Related]
34. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085 [TBL] [Abstract][Full Text] [Related]
35. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Murray-Zmijewski F; Lane DP; Bourdon JC Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753 [TBL] [Abstract][Full Text] [Related]
36. Differential regulation of p63 and p73 expression. Waltermann A; Kartasheva NN; Dobbelstein M Oncogene; 2003 Aug; 22(36):5686-93. PubMed ID: 12944917 [TBL] [Abstract][Full Text] [Related]
37. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. Wang Y; Radhakrishnan D; He X; Peehl DM; Eng C J Clin Endocrinol Metab; 2013 Mar; 98(3):E586-94. PubMed ID: 23386643 [TBL] [Abstract][Full Text] [Related]
38. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Jung MS; Yun J; Chae HD; Kim JM; Kim SC; Choi TS; Shin DY Oncogene; 2001 Sep; 20(41):5818-25. PubMed ID: 11593387 [TBL] [Abstract][Full Text] [Related]
39. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Dohn M; Zhang S; Chen X Oncogene; 2001 May; 20(25):3193-205. PubMed ID: 11423969 [TBL] [Abstract][Full Text] [Related]